Estimating Error Rates in Bioactivity Databases
暂无分享,去创建一个
[1] Pekka Tiikkainen,et al. Analysis of Commercial and Public Bioactivity Databases , 2012, J. Chem. Inf. Model..
[2] Christian Kramer,et al. QSARs, data and error in the modern age of drug discovery. , 2012, Current topics in medicinal chemistry.
[3] Andreas Bender,et al. Databases: Compound bioactivities go public , 2010 .
[4] Sean Ekins,et al. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. , 2012, Drug discovery today.
[5] A. Vulpetti,et al. The experimental uncertainty of heterogeneous public K(i) data. , 2012, Journal of medicinal chemistry.
[6] John P. Overington,et al. Global Analysis of Small Molecule Binding to Related Protein Targets , 2012, PLoS Comput. Biol..
[7] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[8] Peter Murray-Rust,et al. Minimum information about a bioactive entity (MIABE) , 2011, Nature Reviews Drug Discovery.
[9] Sorel Muresan,et al. Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds , 2009, J. Cheminformatics.
[10] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[11] Sorel Muresan,et al. Complementarity between public and commercial databases: new opportunities in medicinal chemistry informatics. , 2007, Current topics in medicinal chemistry.
[12] Sean Ekins,et al. A quality alert and call for improved curation of public chemistry databases. , 2011, Drug discovery today.